|
TRAXION Therapeutics, Inc. Team
Traxion brings together a seasoned group of pharmaceutical
and biotech executives of experience. Each member of the team has over 20
years (in several cases more than 30 years) experience in the development
and commercialization of new drugs. The teams’ relevant skill set
has been built on a track record of success in both the big pharma and
biotech start-up arenas.
President & CEO: (Founder)
Kerrie L. Brady,
BPharm, M.B.A., M.S.
Kerrie is the founder and CEO of Traxion Therapeutics Inc., a newly
established biotech company focused on the development of new drugs to
treat intractable pain. She is an experienced international business
development executive with a successful 20 year plus track record in
working with both entrepreneurial ventures and established companies.
Drawing on her functional expertise in business development, marketing
and regulatory affairs she has forged strategic alliances to bring new
products to market.
Most recently Kerrie was Vice President of Business
Development at KMG Japan Inc. where she established partnerships between
Japanese and Western companies. Her representative recent client base
included; Onyx Pharmaceuticals, Discovery Labs, Guilford, BIO, Arriva,
Bentley, Angionics, ActivBioticis, Combinatorx, Daiichi and Mitsubishi
Pharma. Prior to joining KMG, Kerrie held senior business development
positions with EntreMed, Intracell, and CRC Biopharmaceuticals. Kerrie
began her career in the healthcare industry with regulatory and marketing
positions at Rhone Poulenc.
Commercial
Advisory Board:
James Foley, Ph.D.
Blanche Johnson, Ph.D.
Arthur Michaelis, Ph.D
Scientific
Advisory Board:
Anthony Altar, PhD
James Campbell, MD
Valentin Gribkoff, Ph.D..
Roger Johns, MD
Gavril Pasternak, MD PhD
Legal Counsel:
Whiteford, Taylor & Preston LLP
|
